Medicus Pharma: FDA accepts Type C meeting; Phase 2 BCC study >75% randomized; Q2 net loss $6.2M

Medicus Pharma Ltd.

FDA accepted Type C meeting request; written queries submitted, response expected before end of Q3 2025.
Phase 2 SKNJCT-003 randomized >75% of 90 participants; interim analysis showed >60% clinical clearance.
Cash $9.7M at Q2-end, up from $4.0M Q1; raised $11.5M net from financings and warrant exercises.
Q2 net loss $6.2M vs $3.6M YoY; operating expenses $6.0M vs $3.6M YoY.
CFO James Quinlan exercised 145,000 stock options for ~$156,250 in proceeds.

item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.